2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

9:00AM-11:00AM: Abstract Number: 1566

Prevalence and Prognosis of Interstitial Lung Disease in a Large Cohort of Chinese Primary Sjögren’s Syndrome Patients

Sjögren's Syndrome – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 1605

Prevalence of Anterior Uveitis in Patients with Spondyloarthropathy in a Single US Academic Center: A Retrospective Study from Routine Care

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

9:00AM-11:00AM: Abstract Number: 1614

Prevalence of Sonographic Enthesitis in Patients with Psoriasis without Arthritis and Its Association Risk Factors of Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

9:00AM-11:00AM: Abstract Number: 1646

Prevalence of Spondyloarthritis in Patients with Anterior Uveitis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

9:00AM-11:00AM: Abstract Number: 1129

Prevalence, Incidence, Determinants, and Impacts of Depression and Anxiety in Gout: A Systematic Review

Epidemiology and Public Health Poster II: Gout, Ankylosing Spondylitis, Osteoarthritis, Osteoporosis, Pain, and Function

9:00AM-11:00AM: Abstract Number: 1585

Primary Sjögren’s Syndrome Stratification Based on the Severity of Patient-Reported Fatigue

Sjögren's Syndrome – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 1497

PRISM-RA: A Personalized Medicine Test That Accurately Predicts Rheumatoid Arthritis Patients Who Will Not Respond Adequately to Tumor Necrosis Factor Inhibitors

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1158

Privacy-Preserving Linkage between the Arthritispower Registry and Commercial Payer Claims Data to Support Comparative Effectiveness and Outcomes Research

Epidemiology and Public Health Poster II: Gout, Ankylosing Spondylitis, Osteoarthritis, Osteoporosis, Pain, and Function

9:00AM-11:00AM: Abstract Number: 1088

Pro-Inflammatory and Regulatory Soluble Mediator Pathways Vary between African American and European American SLE Patients

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1480

Prognosis of Pneumonia in Rheumatoid Arthritis Patient: An Analysis of Using a Nationwide Administrative Database

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1744

Prognostic Value of Right Heart Involvement in Systemic Sclerosis:Not Only Pulmonary Arterial Hypertension

Systemic Sclerosis and Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1363

Progression of Pain, Stiffness, Function Changes, and Ultrasound Detected Synovitis and Osteophyte Formation in Patients with Hand Osteoarthritis over Three Years

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1707

Prolactin and Dehydroepiandrosterone Sulfate in Women with Active Systemic Lupus Erythematosus of Recent Onset Versus Chronic Inactive Patients

Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 1684

Prolonged Remission/Low Disease Activity State Is Associated with a Better Health-Related Quality

Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 1727

Prospective Confirmation of Potential Link between Proton Pump Inhibitor Exposure and Calcinosis in Systemic Sclerosis

Systemic Sclerosis and Related Disorders – Clinical Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].